Get the Stockscreener App
40.88
0.42%
0.17
After Hours:
40.88
Gsk Plc Adr stock is traded at $40.88, with a volume of 2.12M.
It is up +0.42% in the last 24 hours and down -6.90% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$40.71
Open:
$40.79
24h Volume:
2.12M
Relative Volume:
0.63
Market Cap:
$83.12B
Revenue:
$39.60B
Net Income/Loss:
$5.10B
P/E Ratio:
11.88
EPS:
3.4423
Net Cash Flow:
$6.48B
1W Performance:
+0.05%
1M Performance:
-6.90%
6M Performance:
-4.64%
1Y Performance:
+12.77%
1-Day Range:
$40.66
$40.93
1-Week Range:
$40.50
$41.42
52-Week Range:
$33.67
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
Global Nicotine Replacement Therapy Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2030 | DelveInsight - GlobeNewswire Inc.
GSK’s Stock Market Adventure: 9.44% YTD Growth Amidst Volatility - The InvestChronicle
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut - Benzinga
GSK Shares Experience Decline in Value - Knox Daily
Anti-retroviral Drugs Market to hit USD 42.5 billion by 2032, says Global Market Insights Inc. - GlobeNewswire Inc.
Ratio Revelations: GSK Plc ADR (GSK)’s Financial Metrics in the Spotlight - The Dwinnex
Why GSK (GSK) is a Top Value Stock for the Long-Term - Yahoo Finance Australia
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Things To Consider Before You Buy GSK Plc ADR (NYSE: GSK) - Stocks Register
Smoking Cessation And Nicotine De-addiction Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire Inc.
GSK Plc ADR [GSK] Is Currently -0.31 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Behind GSK Plc ADR’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation - Benzinga
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults - Benzinga
Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Onychomycosis Market Forecast to Grow at 4.7% CAGR from 2024 to 2031 | SkyQuest Technology - Benzinga
Analysts review GSK Plc ADR’s rating - Knox Daily
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR - GlobeNewswire Inc.
GSK's Respiratory Drug Nucala Meets Goal in COPD Study - MSN
iTeos annonce un taux de réponse objective cliniquement significatif observé à chaque dose lors de l’analyse intermédiaire de suivi de l’étude GALAXIES Lung-201 portant sur l’association belrestotug + dostarlimab dans le traitement de première ligne des patients atteints d’un cancer du poumon non à petites cellules et présentant un taux de PD-L1 élevé - GlobeNewswire Inc.
Evaluating GSK’s financial ratios for a profitable investment - US Post News
Bipolar Disorder Market Size to Reach USD 7 Billion by 2033, Says The Brainy Insights - GlobeNewswire Inc.
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar? - Yahoo Finance
Dietary Supplements Market to Reach USD 63.93 Billion by 2031, Growing at 7.4% CAGR | SkyQuest Technology - Benzinga
Nicotine Replacement Products Market Size to Reach USD 4.6 Billion by 2033, Says The Brainy Insights - GlobeNewswire Inc.
Questex’s Fierce Pharma Announces the 2024 Fierce Pharma Marketing Awards Winners - GlobeNewswire Inc.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance Australia
Ready to Jump After Recent Trade: GSK Plc ADR (GSK) - SETE News
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech - Benzinga
GSK's Respiratory Drug Nucala Meets Goal in COPD Study - Benzinga
GSK's Respiratory Drug Nucala Meets Goal In COPD Study - Barchart
$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region - GlobeNewswire Inc.
GSK Plc ADR (GSK) Stock: A Year of Declines and Increases - The InvestChronicle
Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High - The Motley Fool
Impetigo Drugs Global Strategic Business Report 2024 - GlobeNewswire Inc.
Respiratory Drugs - GlobeNewswire Inc.
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold? - Zacks Investment Research
GSK Plc ADR [GSK] is 19.13% higher this YTD. Is it still time to buy? - The DBT News
Biologics Market Size to Surge to USD 855.8 Billion by 2031 with a 6.9% CAGR, Fueled by Advanced Targeting of Biological Pathways – Report by Transparency Market Research, Inc. - GlobeNewswire Inc.
Premature Ejaculation Treatment Business Research Report 2024 Featuring Absorption Pharma, Allergan, AstraZeneca, Bayer, Eli Lilly and Co, GSK, Innovus, Merck, Pfizer, and Teva - GlobeNewswire Inc.
Simtra BioPharma Solutions ernennt Dr. Lidia Serina zum Head of Development Services - GlobeNewswire Inc.
Is Pfizer Stock Still a Buy After an Unexpected Setback? - The Motley Fool
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.
Cancer Vaccines Market Size Expected to Reach USD 30.16 Bn by 2033 - GlobeNewswire Inc.
Global Medical Nutrition Market Size Anticipated to Surge Past USD 26,555.9 Million Valuation by 2034, Growing at an Average 6.4% CAGR | Future Market Insights, Inc. - GlobeNewswire Inc.
GSK’s Stock Journey: What Investors Need to Know About GSK Plc ADR’s Performance - The InvestChronicle
UK Patient's Perspective on the Corporate Reputation of Pharma, 2023-2024 - GlobeNewswire Inc.
GSK Plc ADR (GSK) Stock: A Year of Stock Market Dynamics - The InvestChronicle
5 Undervalued Stocks That Crushed Earnings - Morningstar
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gsk Plc Adr Stock (GSK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GSK plc | 10% Owner |
Dec 07 '23 |
Buy |
5.00 |
3,300,000 |
16,500,000 |
13,983,761 |
1.63%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):